Several DYRK1A inhibitors have shown promise for improving cognition in rodent models of Down syndrome and Alzheimer's disease, for example, but the ability to affect DYRK1A levels or activity in relevant human cells has not been established. Here, DYRK1A is linked to early-onset autosomal dominant Alzheimer disease.